Prognostic impact of TAZ and β-catenin expression in adenocarcinoma of the esophagogastric junction

Diagnostic Pathology

Table 3 Relationship between the clinicopathologic characteristics of AEG and the expression of TAZ or β-catenin

Clinicopathologic characteristics	TAZ		P	β-catenin (nuclear)		P	β-catenin (membranous)		P	TAZ & β-catenin (nuclear)		P	TAZ & β-catenin (membranous)		P
	Negative	Positive		Negative	Positive		Normal	Abnormal		Others	Positive		Others	Positive
Gender
Male	64	46	0.593	52	58	0.431	45	65	0.312	79	31	0.99	64	46	0.842
Female	16	9	0.593	14	11	0.431	13	12	0.312	18	7	0.99	14	11	0.842
Age
<60 years old	26	22	0.371	13	35	0.001	21	27	0.891	31	17	0.163	22	26	0.037
≥60 years old	54	33	0.371	53	34	0.001	37	50	0.891	66	21	0.163	56	31	0.037
Invasion of serosa
Positive	21	38	0.001	21	38	0.006	18	41	0.010	31	28	0.001	25	34	0.001
Negative	59	17	0.001	45	31	0.006	40	36	0.010	66	10	0.001	53	23	0.001
lymphatic metastasis
Positive	34	42	0.001	30	46	0.013	27	49	0.048	43	33	0.001	37	39	0.015
Negative	46	13	0.001	36	23	0.013	31	28	0.048	54	5	0.001	41	18	0.015
Differentiation
Well-differentiated	51	22	0.007	43	30	0.012	47	26	0.001	59	14	0.012	57	16	0.001
Poorly differentiated	29	33	0.007	23	39	0.012	11	51	0.001	38	24	0.012	21	41	0.001
TNM stage
Stage 0 I II	55	24	0.004	43	36	0.126	39	40	0.074	65	14	0.001	65	32	0.001
Stage III IV	25	31		23	33		19	37		32	24		14	24

ISSN: 1746-1596